|
No description written yet. |
Industry Biotechnology | Homepage crinetics.com |
| Sector Healthcare | IR page ir.crinetics.com | |
|
Tags
—
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 4.232B |
| Market cap (USD) | — |
| P/E | — |
| PEG | — |
| P/BV | 3.55 |
| P/S | — |
| P/OCF | -10.02 |
| P/FCF | -9.95 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -40.2% |
| ROI | -49.9% |
| ROIC | -41.6% |
| Profit margin | -6,046.2% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | -71.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.696M | 1.039M | 4.013M | 0 | 0 | 71K | 1.193M | 2.428M | 2.045M |
| Net profit | -465.317M | -298.408M | -214.529M | -163.918M | -107.641M | -73.812M | -50.422M | -27.115M | -9.157M |
| Free cash flow | -383.684M | -229.814M | -170.995M | -116.861M | -89.024M | -62.213M | -46.873M | -20.518M | -9.783M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | — | — | — | — | — | — | — | — | 0.00 | 592,000 |
| Lease liabilities (USD) | — | — | — | 5.57M | 4.85M | 4.01M | 3.08M | 51.7M | 51.7M | 48.5M |
| Cash and deposits (USD) | 12.2M | 14.2M | 45M | 40.3M | 93.1M | 201M | 32.7M | 54.9M | 265M | 102M |
| Right-of-use assets (USD) | — | — | — | 2.51M | 2.23M | 1.89M | 1.49M | 46.5M | 43.5M | 40.5M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -5.47M | -9.48M | -19.5M | -46.4M | -62M | -88.6M | -115M | -166M | -226M | -378M |
| Purchases of property, plant and equipment (USD) | -190,000 | -304,000 | -1.06M | -492,000 | -186,000 | -436,000 | -1.66M | -4.69M | -3.84M | -5.76M |
| Change in receivables (cash effect) (USD) | — | — | — | — | — | — | — | 0.00 | 0.00 | -592,000 |
| Change in inventories (cash effect) (USD) | — | — | — | — | — | — | — | 0.00 | 0.00 | -2.02M |
| Change in payables (cash effect) (USD) | 300,000 | 47,000 | 7.36M | 696,000 | 2.72M | 6.29M | 11M | 14.6M | 17.5M | 29M |
| Interest paid (cash effect) (USD) | -11,000 | -8,000 | — | — | — | — | — | — | — | — |
| Income taxes paid (cash effect) (USD) | — | — | — | — | — | — | — | 0.00 | 0.00 | -89,000 |
| Share-based compensation (USD) | 270,000 | 271,000 | 2.32M | 6.29M | 10.4M | 17.4M | 28.3M | 40.9M | 69.4M | 91M |
| Operating cash flow before change in receivables (USD) | — | — | — | — | — | — | — | -169M | -230M | -377M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -5.66M | -9.78M | -20.5M | -46.9M | -62.2M | -89M | -117M | -171M | -230M | -384M |
| Income detail | ||||||||||
| Research and development expense (USD) | 5.1M | 9.23M | 24.5M | 41.5M | 57M | 84.3M | 130M | 169M | 240M | 332M |
| ↳ 5y CAGR | +75.2% | +69.8% | +47.1% | +42.1% | +42.3% | |||||
| Total comprehensive income (USD) | -6.02M | -9.16M | -27.1M | -50.3M | -73.9M | -108M | -167M | -210M | -298M | -464M |
| Comprehensive income to owners (USD) | -6.02M | -9.16M | -27.1M | -50.3M | -73.9M | -108M | -167M | -210M | -298M | -464M |
| Reported | Mar 13, 2019 | Mar 13, 2019 | Mar 13, 2019 | Mar 9, 2020 | Mar 30, 2021 | Mar 30, 2022 | Feb 28, 2023 | Feb 26, 2026 | Feb 26, 2026 | Feb 26, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Crinetics Pharmaceuticals, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.